Abstract-Background: Antibody-mediated and cytotoxic T cell-mediated pathogenicity have been implicated as the autoimmune pathophysiologic mechanisms in Rasmussen's encephalitis. Methods: The authors investigated autoantibodies against the NMDA glutamate receptor (GluR)
Epilepsia partialis continua (EPC) is characterized by continuous myoclonic jerks of the extremities, face, etc., usually without impairment of consciousness. The clinical evolution of EPC is variable, depending on the patient's age and underlying brain diseases.
1,2 EPC was classified into two groups: a group with stable neurologic deficit, and another group with slowly progressive neurologic deficit. 3 The latter cases are classified as chronic progressive EPC of childhood in the revised classification of epileptic syndromes, 4 which may be diagnosed as Rasmussen's encephalitis [5] [6] [7] upon histologic confirmation. Histologic examination revealed infiltration of T lymphocytes and microglia cells, astrocytosis, and neuronal loss. 6, 8, 9 As glutamate receptor 3 (GluR3) was reported as an autoantigen in Rasmussen's encephaAdditional material related to this article can be found on the Neurology Web site. Go to www.neurology.org and scroll down the Table of Contents for the October 14 issue to find the title link for this article. -litis, 10 epilepsies causally related to autoantibodies are highlighted.
The ionotropic GluRs are subdivided into three major subtypes: NMDA, ␣-amino-3-hydroxy-5-methyl-4-isoxazole propionate, and kainate receptors. The NMDA GluR are heterodimers composed of GluR ⑀ (⑀1 to ⑀4) (NMDAR2A to 2D) and GluR 1 (NMDAR1) subunits. 11 GluR ⑀2 is the essential molecule for synaptic plasticity and development. 12 In Rasmussen's encephalitis, not only epileptic seizures but also impairment of higher brain functions (e.g., mental retardation and visual disturbance) occur frequently. Therefore, we examined autoantibodies against NMDA GluR ⑀2 and their epitopes in sera and CSF in patients with chronic forms of EPC and Rasmussen's encephalitis to estimate the immunologic aspects in the impairment of higher brain functions. We could not examine autoantibodies against the GluR3 subunit because its cDNA was unavailable. 15 and neuropsychological impairment (clinical Rasmussen type). In the clinical Rasmussen type, three patients (Patients 1 to 3) with infantile onset manifested quadriplegia shortly after the onset, which was not typical for Rasmussen's encephalitis. Bilateral involvement in patients with Rasmussen's encephalitis was reported in infantile patients 2, 16 and adult patients. 16 Serum samples from 11 healthy children were also examined as controls. Informed consent was obtained from each patient or guardian after oral or written explanation according to the ethical principles of the Declaration of Helsinki.
Establishment of stable transformant cells expressing GluR ⑀2. Using the tetracycline induction system, 17 cDNA of GluR ⑀2, 18 pSTneoB, 19 and G418 selection, 20 we established stable NIH3T3 transformant cell lines expressing full-length GluR ⑀2 (B18) and GluR ␦2 subunits (see the supplementary material on the Neurology Web site). Identification of three clones with integrated cDNA of GluR ⑀2 was done by PCR (see figure E-1A on the Neurology Web site). Western blot was used to confirm the expression of GluR ⑀2 protein after 48-hour culture with doxycycline (see figure E-1B on the Neurology web site).
Detection of autoantibodies against GluR ⑀2 in sera and CSF. Supernatants of cell extracts from B18 and the control cell line (A1) cultured for 48 hours with doxycycline (1 g/mL) were subjected to sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), and the gels were transferred to nitrocellulose membranes. Each membrane was cut into 20 strips after overnight blocking with the blocking buffer (0.02 M Tris-HCl, 0.16 M NaCl, 0.05% bovine serum albumin). The strips of B18 and A1 were reacted with sera (diluted 20-fold with blocking buffer) or CSF (diluted 15-fold with blocking buffer) for 48 hours at 4°C and were stained by alkaline phosphatase-labeled second antibodies (IgG, IgA, or IgM; Jackson ImmunoResearch, West Grove, PA). The presence of autoantibodies against GluR ⑀2 was judged by a positively stained band with molecular size of about 180 kd, which was found only on the B18 strip and not on the A1 strip (figure 1). As B18 cells cultured without doxycycline showed leaked expression of GluR ⑀2 (see figure E-1B on the Neurology Web site), we used A1 (see the supplementary material on the Neurology Web site) as control. The presence of autoantibodies against GluR ⑀2 was recognized usually in patients' sera diluted Ͻ400-fold (data not shown). Because the concentration of GluR ⑀2 cannot be measured in each supernatant of homogenates of B18 cells, we examined the autoantibodies in 20-fold-diluted sera to reduce falsenegative results. Data obtained by 48-hour incubation at the first EPC ϭ epilepsia partialis continua; DPT ϭ diphtheria-pertussis-tetanus; status ϭ status epilepticus; CPS ϭ complex partial seizure; SPS ϭ simple partial seizure; QP ϭ quadriplegia; HP ϭ hemiplegia; HA ϭ hemianopsia; MR ϭ mental retardation.
step showed clearer positive bands than those by 24-hour incubation (data not shown).
Preparation of bacterial fusion proteins containing peptides from the GluR ⑀2 subunit. DNA fragments encoding amino acid residues 1 to 48 (an amino-terminal peptide; N), 998 to 1,074 (a carboxyl-terminal peptide; C1), 1,053 to 1,153 (a carboxyl-terminal peptide; C2), and 1,353 to 1,432 (a carboxyl-terminal peptide; C3) were amplified by PCR using appropriate synthetic oligonucleotides. The positions of candidate epitopes were determined considering molecular interactions. The fragments were cloned to the bacterial fusion protein expression plasmid vector pGEX-4T-2 (Pharmacia Biotech AB, Uppsala, Sweden) or pMAL (New England Biolabs, Beverly, MA) for the production of fusion protein with glutathione S-transferase (GST) or maltose-binding protein 21 (see figure E-2 on the Neurology Web site). The expression plasmids were transformed into Escherichia coli (BL21 or TB1), and subsequent induction with isopropyl-␤-D-thiogalactopyranoside was performed by routine methods. 22 The transformed E. coli were sonicated to obtain supernatants of the bacterial homogenates.
Epitope analyses of autoantibodies against GluR ⑀2 in sera and CSF. Supernatants of bacterial homogenates that contained induced GluR ⑀2 polypeptide fusion proteins synthesized by the above methods were subjected to SDS-PAGE, and the proteins in gels were transferred to nitrocellulose membranes. Each membrane was reacted with serum or CSF (diluted 20-or 15-fold with blocking buffer) for 48 hours at 4°C and stained by alkaline phosphatase-labeled second antibodies (IgG or IgM). A positive reaction with an epitope was judged by a stained band at the appropriate molecular weight (figure 2).
Results. Autoantibodies against GluR ⑀2 molecules in sera from patients with chronic EPC. Autoantibodies against GluR ⑀2 molecule were studied in the sera of 15 patients with chronic EPC (table 2) . Thirteen of 15 patients had IgG autoantibodies against GluR ⑀2 molecule during the course of disease, and 8 of 13 patients had both IgG and IgM autoantibodies. None of the patients we examined had IgA autoantibodies against GluR ⑀2. The frequencies of IgG and IgM autoantibodies against GluR ⑀2 in each category of patients were three and one of three in definitive Rasmussen type, six and four of seven in clinical Rasmussen type, two and two of three in acute type, and two and one of two in nonprogressive type, respectively.
In Patient 1, autoantibodies against GluR ⑀2 were negative shortly after the onset of epilepsy and evolutionally became positive. In Patient 1, both IgM and IgG autoantibodies were negative at the age of 0.8 years when he started to have catastrophic epilepsy. Then, the autoantibodies appeared at age 0.9 years with persistent catastrophic epilepsy and were followed by the appearance of EPC. Therefore, the early stage of catastrophic epilepsy was associated with absence of autoantibodies against the NMDA GluR ⑀2 subunit. In Patient 5, after IV high-dose ␥-globulin infusion therapy (200 mg/kg wt, 5 days), EPC remitted and complex partial seizures decreased to yearly occurrence, accompanied by negative autoantibodies at the age of 5.2 years. At age 7.3 years, EPC recurred and the autoantibodies again became positive. Thus, Patient 5 showed fluctuation of autoantibodies in relation to the severity of clinical symptoms modulated by immunotherapy. Although Patient 3 had no autoantibodies against GluR ⑀2, the test was done at the residual stage 7 when EPC and complex partial seizures had both remitted.
In all four patients who were followed for periods of Ͼ2 years (Patients 1, 2, 5, and 9), serum IgM autoantibodies were found in the early phase of EPC and became negative later.
Autoantibodies against cerebellar Purkinje cell-specific GluR ␦2 were examined in 11 patients except Patients 4, Figure 1 
kd (N), 34 kd (C1), 33 kd (C3), and 58 kd (C2). The large band in lane M is carbonic anhydrase (about 43 kd).
11, 13, and 15, and all the results were negative (data not shown).
No autoantibodies against GluR ⑀2 molecule were detected in the sera of 17 patients with West syndrome, 10 patients with Lennox-Gastaut syndrome, and 11 control subjects.
Autoantibodies against GluR ⑀2 molecules in CSF from patients with chronic EPC. IgG and IgM autoantibodies 
Age at exam ϭ age at examination of autoantibodies; EPC ϭ epilepsia partialis continua; Ext ϭ involvement of extremities by EPC; Face ϭ EPC on facial muscles, tongue, or throat; CPS ϭ complex partial seizures; D ϭ daily; W ϭ weekly; M ϭ monthly; Y ϭ yearly; C ϭ controlled; GluR ϭ glutamate receptor; NT ϭ not tested; (ϩ) ϭ presence of autoantibodies; (Ϫ) ϭ absence of autoantibodies.
against
Epitope analyses of autoantibodies against GluR ⑀2 in sera and CSF from patients with chronic EPC. IgG autoantibodies against the putative epitopes (N, C1, C2, and C3) of the GluR ⑀2 molecule were examined using bacterial fusion proteins containing the corresponding GluR ⑀2 polypeptides (see figure E-2 on the Neurology Web site; also see figure 2 ). Among 13 patients with IgG autoantibodies against the GluR ⑀2 molecule, 3 patients had serum autoantibodies to N epitope, 6 had autoantibodies to C1, 11 had autoantibodies to C2, and 9 had autoantibodies to C3 (see table 2 ). Autoantibodies to C2 epitope predominated, whereas autoantibodies to the extracellular N epitope were rare. The epitope recognition profile was not consistent during the course of disease in almost all patients examined repeatedly (Patients 1, 2, 5 to 8, 12 ). The CSF of Patients 2, 6, 7, and 12 reacted with all epitopes (N, C1, C2, and C3); CSF of Patients 4, 8, and 11 reacted with three epitopes (except C1); and CSF of Patient 14 reacted with two epitopes (C1 and C3). The spectra of epitope recognition of the autoantibodies were broader in the CSF than in the serum in almost all patients, judging from simultaneously collected samples.
In Patients 2, 7, 8, and 12, IgG autoantibodies in sera and/or CSF reacted with increasing numbers of epitopes as disease progressed. In Patient 1, the number of epitopes increased from one to three, accompanying onset of EPC, and decreased with remission of EPC, whereas the numbers of epitopes showed no temporal increase in Patients 5 and 6.
Discussion. Autoantibodies against whole NMDA GluR ⑀2 molecule in the serum were detected in 13 of 15 patients with chronic EPC and not in patients with West syndrome, Lennox-Gastaut syndrome, or controls. In patients with chronic EPC, three of three definitive Rasmussen-type patients, six of seven clinical Rasmussen-type patients, two of two nonprogressive-type patients, and two of three acutetype patients had autoantibodies against whole NMDA GluR ⑀2. The IgM autoantibodies changed from positive to negative in definitive or clinical Rasmussen-type patients. The autoantibodies against NMDA GluR ⑀2 fluctuated in accordance with disease severity in some patients. We detected no autoantibodies against GluR ␦2 in sera at the same dilution as autoantibodies against GluR ⑀2 in patients with chronic EPC. These data suggest that autoantibodies against NMDA GluR ⑀2 might be causally related to intractable partial seizures, especially EPC, not to generalized seizures in patients with West syndrome or Lennox-Gastaut syndrome. The presence of autoantibodies against NMDA GluR ⑀2 might suggest the involvement of autoimmune pathologic mechanisms but is not a hallmark of Rasmussen's encephalitis.
Other than autoantibodies against GluR3 and GluR ⑀2, autoantibodies against neuronal acetylcholine receptor ␣ 7 subunit 23 and munc-18 24 have been also reported in patients with Rasmussen's encephalitis. Patient 10 in our study had a negative test for anti-GluR3 autoantibodies in another hospital but was found to have autoantibodies against GluR ⑀2. Furthermore, autoantibodies against GluR3 were found in only 25% of patients with Rasmussen's encephalitis in a recent report 25 and were detected also in neurologic diseases other than Rasmussen's encephalitis [25] [26] [27] and controls. 25 We speculate that Rasmussen's encephalitis is not associated with specific autoantibodies, and various autoantibodies against neural molecules might contribute to the pathologic process. Although we could not examine autoantibodies against GluR3, patients with Rasmussen's encephalitis might have several kinds of autoantibodies against neural molecules, including GluR3 and GluR ⑀2.
In our patients with definitive and clinical Rasmussen's encephalitis, the spectra of epitope recognition of the autoantibodies against GluR ⑀2 were broader in the CSF than in the serum, judging from simultaneously collected samples. Furthermore, our examination of the autoantibodies was done almost at the same dilution in sera (20-fold) and CSF (15-fold), but the prevalence of the autoantibodies in CSF was as same as in sera. This may suggest relatively higher concentration of the autoantibodies in CSF compared with ordinary infectious diseases. Thus, our data might suggest that serum autoantibodies against GluR ⑀2 are not generated in peripheral circulation by molecular mimicry following infection but are generated in the CNS.
In Patients 2, 7, 8, and 12, the epitopes recognized by IgG autoantibodies increased with disease progression in sera and/or CSF, and in Patient 1, the number of epitopes increased from one to three, accompanying onset of EPC, and decreased with remission of EPC. These phenomena might suggest "epitope spreading," 28 which is the mechanism of autoimmune disease mediated by T cells. The predominance of autoantibodies against intracellular C-terminal epitopes of GluR ⑀2 also suggests the involvement of T cell-mediated autoimmunity in Rasmussen's encephalitis, because T cells, and not B cells, can recognize the cytoplasmic domains of transmembranous molecules.
Mice immunized with the GluR3B peptide produced autoantibodies but exhibited no epilepsy, even by facilitated entry of the autoantibodies into the brain. 29 Furthermore, lymphocytic infiltration of predominantly T cells and sparse B cells were reported in resected tissues of Rasmussen's encephalitis patients, 9 and local CNS immune responses in Rasmussen's encephalitis included local-clonal expansion of T cells responding to discrete antigen epitopes. 30 
CD8
ϩ T-cell cytotoxicity was reported to contribute to the pathogenesis of Rasmussen's encephalitis, and neuronal loss resulting from cytotoxic T-cell attack and concomitant release of antigens such as GluR3 were estimated to generate secondary antibodymediated damage. 31, 32 These observations suggest that the primary cause of Rasmussen's encephalitis is not autoantibodies but T cell-mediated autoimmunity. Also from our data, probable heterogeneity of autoantibodies in Rasmussen's encephalitis, epitope spreading, and predominant intracellular epitopes of autoantibodies against the NMDA GluR ⑀2 suggest an important role of T cell-mediated autoimmunity.
Although the presence of autoantibodies against GluR ⑀2 is not a hallmark of Rasmussen's encephalitis, the autoantibodies are important for the diagnosis of Rasmussen's encephalitis, especially in patients without EPC, which is a typical clinical diagnostic marker of Rasmussen's encephalitis, and suggest the indication of immunosuppressive therapies against cytotoxic T cells.
